check_circleStudy Completed
Hypertension, Pulmonary
Bayer Identifier:
17983
ClinicalTrials.gov Identifier:
EudraCT Number:
Not Available
EU CT Number:
Not Available
A study to understand the treatment patterns in patients with Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension during a switch of treatment to Adempas in real-life clinical practice
Trial purpose
The aim of this study is to understand the treatment patterns in patients with Pulmonary Arterial Hypertension (PAH) or Chronic Thromboembolic Pulmonary Hypertension (CTEPH) during a switch of treatment to Adempas in real-life clinical practice.
In addition, this study will describe patient demographics and reason for switching
In addition, this study will describe patient demographics and reason for switching
Key Participants Requirements
Sex
BothAge
NaN - N/ATrial summary
Enrollment Goal
125Trial Dates
September 2015 - August 2016Phase
N/ACould I Receive a placebo
NoProducts
Adempas (Riociguat, BAY63-2521)Accepts Healthy Volunteer
NoWhere to participate
Status | Institution | Location |
---|---|---|
Completed | Many Locations, Germany | |
Withdrawn | Many Locations, United Kingdom | |
Completed | Many Locations, Japan | |
Completed | Many Locations, Canada | |
Completed | Many Locations, Belgium | |
Completed | Many Locations, Sweden | |
Withdrawn | Many Locations, Denmark | |
Completed | Many Locations, Turkey | |
Completed | Many Locations, Colombia |
Primary Outcome
- Starting Dosedate_rangeTime Frame:Up to a total of 8 weeks of titration periodenhanced_encryptionNoSafety Issue:
- Dose Incrementsdate_rangeTime Frame:Up to a total of 8 weeks of titration periodenhanced_encryptionNoSafety Issue:
- Final Dosedate_rangeTime Frame:Up to a total of 8 weeks of titration periodenhanced_encryptionNoSafety Issue:
Trial design
Trial Type
ObservationalIntervention Type
DrugTrial Purpose
N/AAllocation
N/ABlinding
N/AAssignment
N/ATrial Arms
N/A